CSF-1R-dependent lethal hepatotoxicity when agonistic CD40 antibody is given before but not after chemotherapy

Journal of Immunology

Volumn 197, Issue 1, 2016, Pages 179-187

  Byrne, Katelyn T ^a   Leisenring, Nathan H ^a   Bajor, David L ^a   Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD40 MONOCLONAL ANTIBODY; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL; UNCLASSIFIED DRUG; CD40 ANTIGEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; LIVER TOXICITY; MACROPHAGE ACTIVATION; MORTALITY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR REGRESSION; AGONISTS; ANIMAL; C57BL MOUSE; CARCINOMA, DUCTAL; CLINICAL PROTOCOL; COMPLICATION; DRUG INTERACTION; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXPERIMENTAL NEOPLASM; GENETIC ENGINEERING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LIVER FAILURE; METABOLISM; PANCREATIC NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CARCINOMA, DUCTAL; CELL LINE, TUMOR; CLINICAL PROTOCOLS; DRUG INTERACTIONS; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; LIVER FAILURE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

EID: 84975299411     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600146     Document Type: Article

References (41)

1. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
2. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
3. Robert, C., J. Schachter, G. V. Long, A. Arance, J. J. Grob, L. Mortier, A. Daud, M. S. Carlino, C. McNeil, M. Lotem, et al; KEYNOTE-006 Investigators. 2015. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372: 2521-2532.
4. Sharma, P., and J. P. Allison. 2015. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161: 205-214.
5. Tumeh, P. C., C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571.
6. Sausen, M., J. Phallen, V. Adleff, S. Jones, R. J. Leary, M. T. Barrett, V. Anagnostou, S. Parpart-Li, D. Murphy, Q. Kay Li, et al. 2015. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat. Commun. 6: 7686.
7. Jones, S., X. Zhang, D. W. Parsons, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
8. Alexandrov, L. B., S. Nik-Zainal, D. C. Wedge, S. A. J. R. Aparicio, S. Behjati, A. V. Biankin, G. R. Bignell, N. Bolli, A. Borg, A.-L. Børresen-Dale, et al. 2013. Signatures of mutational processes in human cancer. Nature 500: 415-421.
9. Burris, H. A., III, M. J. Moore, J. Andersen, M. R. Green, M. L. Rothenberg, M. R. Modiano, M. C. Cripps, R. K. Portenoy, A. M. Storniolo, P. Tarassoff, et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 15: 2403-2413.
10. Le, D. T., E. Lutz, J. N. Uram, E. A. Sugar, B. Onners, S. Solt, L. Zheng, L. A. Diaz, Jr., R. C. Donehower, E. M. Jaffee, and D. A. Laheru. 2013. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36: 382-389.
11. Royal, R. E., C. Levy, K. Turner, A. Mathur, M. Hughes, U. S. Kammula, R. M. Sherry, S. L. Topalian, J. C. Yang, I. Lowy, and S. A. Rosenberg. 2010. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33: 828-833.
12. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
13. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
14. Ridge, J. P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474-478.
15. Sotomayor, E. M., I. Borrello, E. Tubb, F. M. Rattis, H. Bien, Z. Lu, S. Fein, S. Schoenberger, and H. I. Levitsky. 1999. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5: 780-787.
16. Beatty, G. L., E. G. Chiorean, M. P. Fishman, B. Saboury, U. R. Teitelbaum, W. Sun, R. D. Huhn, W. Song, D. Li, L. L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616.
17. Nowak, A. K., B. W. Robinson, and R. A. Lake. 2003. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63: 4490-4496.
18. Hingorani, S. R., L. Wang, A. S. Multani, C. Combs, T. B. Deramaudt, R. H. Hruban, A. K. Rustgi, S. Chang, and D. A. Tuveson. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483.
19. Westcott, P. M., K. D. Halliwill, M. D. To, M. Rashid, A. G. Rust, T. M. Keane, R. Delrosario, K. Y. Jen, K. E. Gurley, C. J. Kemp, et al. 2015. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517: 489-492.
20. Clark, C. E., S. R. Hingorani, R. Mick, C. Combs, D. A. Tuveson, and R. H. Vonderheide. 2007. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67: 9518-9527.
21. Winograd, R., K. T. Byrne, R. A. Evans, P. M. Odorizzi, A. R. Meyer, D. L. Bajor, C. Clendenin, B. Z. Stanger, E. E. Furth, E. J. Wherry, and R. H. Vonderheide. 2015. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol. Res. 3: 399-411.
22. Beatty, G. L., R. Winograd, R. A. Evans, K. B. Long, S. L. Luque, J. W. Lee, C. Clendenin, W. L. Gladney, D. M. Knoblock, P. D. Guirnalda, and R. H. Vonderheide. 2015. Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4/80(+) extratumoral macrophages. Gastroenterology 149: 201-210.
23. Olive, K. P., M. A. Jacobetz, C. J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M. A. Goldgraben, M. E. Caldwell, D. Allard, et al. 2009. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324: 1457-1461.
24. Lo, A., L. C. Wang, J. Scholler, J. Monslow, D. Avery, K. Newick, S. O'Brien, R. A. Evans, D. J. Bajor, C. Clendenin, et al. 2015. Tumor-promoting desmoplasia Is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 75: 2800-2810.
25. Frese, K. K., A. Neesse, N. Cook, T. E. Bapiro, M. P. Lolkema, D. I. Jodrell, and D. A. Tuveson. 2012. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2: 260-269.
26. Zhu, Y., B. L. Knolhoff, M. A. Meyer, T. M. Nywening, B. L. West, J. Luo, A. Wang-Gillam, S. P. Goedegebuure, D. C. Linehan, and D. G. DeNardo. 2014. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74: 5057-5069.
27. Hollenbaugh, D., N. Mischel-Petty, C. P. Edwards, J. C. Simon, R. W. Denfeld, P. A. Kiener, and A. Aruffo. 1995. Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 182: 33-40.
28. Afford, S. C., S. Randhawa, A. G. Eliopoulos, S. G. Hubscher, L. S. Young, and D. H. Adams. 1999. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J. Exp. Med. 189: 441-446.
29. Zhou, F., M. N. Ajuebor, P. L. Beck, T. Le, C. M. Hogaboam, and M. G. Swain. 2005. CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis. Hepatology 42: 372-380.
30. Medina-Echeverz, J., C. Ma, A. G. Duffy, T. Eggert, N. Hawk, D. E. Kleiner, F. Korangy, and T. F. Greten. 2015. Systemic agonistic anti-CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver lamage. Cancer Immunol. Res. 3: 557-566.
31. Vonderheide, R. H., and M. J. Glennie. 2013. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19: 1035-1043.
32. Melero, I., S. Hervas-Stubbs, M. Glennie, D. M. Pardoll, and L. Chen. 2007. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7: 95-106.
33. Bajor, D. L., X. Xu, D. A. Torigian, R. Mick, L. R. Garcia, L. P. Richman, C. Desmarais, K. L. Nathanson, L. M. Schuchter, M. Kalos, and R. H. Vonderheide. 2014. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol. Res. 2: 1051-1058.
34. Vonderheide, R. H., K. T. Flaherty, M. Khalil, M. S. Stumacher, D. L. Bajor, N. A. Hutnick, P. Sullivan, J. J. Mahany, M. Gallagher, A. Kramer, et al. 2007. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25: 876-883.
35. Carmichael, J., U. Fink, R. C. Russell, M. F. Spittle, A. L. Harris, G. Spiessi, and J. Blatter. 1996. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 73: 101-105.
36. Anderson, H., B. Lund, F. Bach, N. Thatcher, J. Walling, and H. H. Hansen. 1994. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J. Clin. Oncol. 12: 1821-1826.
37. Green, M. R. 1996. Gemcitabine safety overview. Semin. Oncol. 23(5Suppl. 10): 32-35.
38. Fransen, M. F., M. Sluijter, H. Morreau, R. Arens, and C. J. Melief. 2011. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin. Cancer Res. 17: 2270-2280.
39. Bouchlaka, M. N., G. D. Sckisel, M. Chen, A. Mirsoian, A. E. Zamora, E. Maverakis, D. E. Wilkins, K. L. Alderson, H. H. Hsiao, J. M. Weiss, et al. 2013. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J. Exp. Med. 210: 2223-2237.
40. Mirsoian, A., M. N. Bouchlaka, G. D. Sckisel, M. Chen, C. C. Pai, E. Maverakis, R. G. Spencer, K. W. Fishbein, S. Siddiqui, A. M. Monjazeb, et al. 2014. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J. Exp. Med. 211: 2373-2383.
41. Gavins, F. N., G. Li, J. Russell, M. Perretti, and D. N. Granger. 2011. Microvascular thrombosis and CD40/CD40L signaling. J. Thromb. Haemost. 9: 574-581.